BLND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BLND is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The company’s business momentum is improving, but the stock is still in a weak technical downtrend, there is no strong proprietary buy signal, and analyst targets remain only modestly above the current price. For an impatient investor who does not want to wait for an ideal entry, this is still more of a hold than an immediate buy.
Price is 1.41, slightly above the previous close of 1.39, but the broader picture is weak. MACD histogram is negative and worsening, RSI_6 at 37.98 shows weak but not oversold momentum, and the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5. Key support is 1.255 and resistance starts at 1.648, so the stock is trading in a fragile range near support rather than in a confirmed uptrend. The short-term statistical trend suggests only modest upside over the next week and month.
Q1 2026 revenue grew 15% year over year to $30.8 million, with non-GAAP operating income of $4.1 million. The company signed 15 new deals in the quarter, including an eClose agreement with a top-20 bank. Autopilot appears to be gaining traction, with 65 lenders activated, 22 live, and over 7,000 applications processed. Management guided Q2 revenue to $32 million-$34 million, which supports continued growth momentum.
The stock is still in a bearish technical structure and has not confirmed a trend reversal. Analyst targets were cut across multiple firms in early May and March, reflecting caution around the business outlook. Q2 guidance was described as disappointing by some analysts, and elevated interest rates continue to pressure forward estimates. There is no AI Stock Picker signal and no SwingMax signal, so there is no proprietary catalyst supporting an immediate entry. Hedge fund and insider activity are both neutral, with no notable buying support. No recent congress trading data is available.
Latest quarter was Q1 2026. Revenue rose 15% year over year to $30.8 million, which is a healthy growth rate. The company also produced $4.1 million of non-GAAP operating income, showing improving profitability. The key trend is that core execution is improving and deal activity is expanding, but the company remains tied to mortgage and lending cycle conditions.
Analyst sentiment is mixed but slightly positive overall. Goldman Sachs kept a Buy rating but lowered its target to $3.50 from $4. Citizens kept an Outperform rating but cut its target to $4 from $5, citing strong Q1 results but disappointing Q2 guidance. Keefe Bruyette cut its target to $1.90 and kept Market Perform, while UBS kept Neutral and lowered its target to $2. Overall, Wall Street sees some upside potential and improving product traction, but recent target cuts show caution and the consensus is not strongly bullish at the current price.
